Shandong Boan Signs Licensing Deal for Denosumab in Japan

PUBT · 3d ago
Shandong Boan Signs Licensing Deal for Denosumab in Japan
  • Shandong Boan Biotechnology entered a licensing agreement with a partner for BA6101, its 60 mg denosumab injection, in Japan.
  • The partner receives exclusive commercialization rights in Japan, including regulatory submissions, with full responsibility for market access.
  • Boan will receive an upfront payment, milestone payments and sales royalties.
  • BA6101 references Pralia, whose Japan sales reached JPY 45.8 billion in FY2025, up 8.3% year-on-year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12390313), on October 30, 2026, and is solely responsible for the information contained therein.